Ultragenyx Pharmaceutical RARE Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's operating cash flow?
- Ultragenyx Pharmaceutical (RARE) reported operating cash flow of -$197M in Q1 2026.
- How has Ultragenyx Pharmaceutical's operating cash flow changed year-over-year?
- Ultragenyx Pharmaceutical's operating cash flow decreased by 18.7% year-over-year, from -$166M to -$197M.
- What is the long-term trend for Ultragenyx Pharmaceutical's operating cash flow?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's operating cash flow has grown at a 8.3% compound annual growth rate (CAGR), from -$338.7M to -$466M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.